Somewhat Positive Press Coverage Somewhat Unlikely to Affect Pfizer (PFE) Share Price
News coverage about Pfizer (NYSE:PFE) has been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Pfizer earned a daily sentiment score of 0.06 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 46.4148166933474 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the headlines that may have impacted Accern Sentiment Analysis’s rankings:
- Investors need to focus on Analysts Rating: Pfizer Inc. (PFE) – Wall Street Morning (wallstreetmorning.com)
- Pfizer (PFE) and Delta Air Lines (DAL): Growth & Income Stocks – Nasdaq (nasdaq.com)
- Suggestions before Buy or Sell action Pfizer Inc. (PFE) – Nasdaq Chronicle (nasdaqchronicle.com)
- Valeant: Pfizer’s Ulcerative Colitis Drug Could Sting – Seeking Alpha (seekingalpha.com)
- Assessing Pfizer’s 4Q17 Quarterly Revenue Trend (finance.yahoo.com)
PFE has been the topic of a number of recent analyst reports. BMO Capital Markets set a $39.00 target price on Pfizer and gave the stock a “buy” rating in a research note on Tuesday, January 30th. SunTrust Banks reaffirmed a “hold” rating and set a $40.00 target price (up previously from $33.00) on shares of Pfizer in a report on Monday, January 29th. Morgan Stanley boosted their target price on Pfizer from $41.00 to $43.00 and gave the stock a “buy” rating in a research report on Wednesday, January 31st. UBS Group set a $42.00 price objective on Pfizer and gave the company a “buy” rating in a research report on Wednesday, January 31st. Finally, Societe Generale set a $40.00 price objective on Pfizer and gave the company a “neutral” rating in a research report on Wednesday, January 31st. Two analysts have rated the stock with a sell rating, ten have given a hold rating and eleven have issued a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $39.40.
Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.62 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.56 by $0.06. Pfizer had a return on equity of 25.21% and a net margin of 40.55%. The business had revenue of $13.70 billion during the quarter, compared to analyst estimates of $13.67 billion. During the same period in the previous year, the company posted $0.47 EPS. Pfizer’s revenue was up .6% on a year-over-year basis. research analysts forecast that Pfizer will post 2.95 earnings per share for the current year.
Pfizer declared that its Board of Directors has initiated a share buyback plan on Monday, December 18th that authorizes the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization authorizes the biopharmaceutical company to repurchase shares of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s management believes its stock is undervalued.
The business also recently declared a quarterly dividend, which was paid on Thursday, March 1st. Stockholders of record on Friday, February 2nd were issued a $0.34 dividend. The ex-dividend date was Thursday, February 1st. This is an increase from Pfizer’s previous quarterly dividend of $0.32. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.72%. Pfizer’s dividend payout ratio (DPR) is currently 38.75%.
In related news, insider Kirsten Lund-Jurgensen sold 9,510 shares of the business’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $37.19, for a total transaction of $353,676.90. Following the transaction, the insider now directly owns 36,959 shares in the company, valued at approximately $1,374,505.21. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director W Don Cornwell sold 1,758 shares of the business’s stock in a transaction dated Tuesday, February 27th. The shares were sold at an average price of $36.79, for a total value of $64,676.82. Following the sale, the director now owns 1,000 shares in the company, valued at approximately $36,790. The disclosure for this sale can be found here. Insiders sold a total of 248,037 shares of company stock worth $9,064,785 over the last quarter. Company insiders own 0.06% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Affect Pfizer (PFE) Share Price” was posted by Marea Informative and is owned by of Marea Informative. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.mareainformativa.com/2018/03/16/pfizer-pfe-receiving-somewhat-positive-media-coverage-analysis-finds-updated-updated-updated.html.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.